The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Immunotherapy firm Harpoon Therapeutics Inc. raised $70mm through its Series C round. Lead investor OrbiMed was joined by other new investors Cormorant, Ridgeback Capital, Lilly Asia Investments, and NS Investment, along with returning backers MPM Capital, Oncology Impact Fund (under MPM), Arix Bioscience (invested $8mm and retains its 11.3% stake), New Leaf Venture Partners, and Taiho Ventures. Proceeds will support advancement of candidates discovered with the company's TriTAC (Tri-specific T cell Activating Construct) and ProTriTAC (Protease-activated Tri-specific T Cell Activating Construct) platforms, including HPN424 (Phase I for prostate cancer) and preclinical projects HPN536 (mesothelin-expressing tumors) and HPN217 (multiple myeloma).

+ Show All | – Hide All


Click a figure for comparable deals.

Potential Deal Value $70.00mm
Transactions 1 of 1 (11/2018)
Round # 3
Funding Stage Additional Round
Equity $70.00mm
Total Line Value $70.00mm
Gross Proceeds $70.00mm
Investors Arix Bioscience PLC
Cormorant Asset Management
Lilly Asia Ventures
MPM Capital
NS Investment
New Leaf Venture Partners
OrbiMed Advisors LLC
Ridgeback Capital Management
Taiho Ventures

Deal Information

Click a keyword for comparable deals.

Deal Industry Biotechnology
Large Molecule
Deal Status Final
Deal Type Financing
Private Placement

Company Information

Click a keyword for comparable companies.

Harpoon Therapeutics Inc.
View Company Profile | View Company Deals
Company Location Worldwide
North America
Industry Biotechnology
Large Molecule
Description Start-Up
Ownership Private
Therapeutic Area(s) of Focus Cancer